Celyad SA (Belgium) Executives
CYAD Stock | EUR 0.71 0.06 7.79% |
Celyad SA employs about 95 people. The company is managed by 33 executives with a total tenure of roughly 167 years, averaging almost 5.0 years of service per executive, having 2.88 employees per reported executive. Discussion of Celyad SA's management performance can provide insight into the enterprise performance.
Filippo Petti CEO Chief Executive Officer, Chief Financial Officer, Director |
Michel Lussier Chairman Chairman of the Board, Co-Founder |
Celyad |
Celyad SA Management Team Effectiveness
The company has return on total asset (ROA) of (0.2933) % which means that it has lost $0.2933 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.9264) %, meaning that it generated substantial loss on money invested by shareholders. Celyad SA's management efficiency ratios could be used to measure how well Celyad SA manages its routine affairs as well as how well it operates its assets and liabilities.Celyad SA Workforce Comparison
Celyad SA is number one stock in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 772. Celyad SA retains roughly 95.0 in number of employees claiming about 12% of equities under Health Care industry.
Celyad SA Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Celyad SA Price Series Summation is a cross summation of Celyad SA price series and its benchmark/peer.
Celyad SA Notable Stakeholders
A Celyad SA stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Celyad SA often face trade-offs trying to please all of them. Celyad SA's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Celyad SA's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Filippo Petti | Chief Executive Officer, Chief Financial Officer, Director | Profile | |
Michel Lussier | Chairman of the Board, Co-Founder | Profile | |
Carri Duncan | Vice President Corporate Development and Communications | Profile | |
Richard Mountfield | Vice President of Global Regulatory Affairs | Profile | |
Peter Waele | Member of the Executive Management Committee, Vice President - Research & Development | Profile | |
Georges Rawadi | Vice President - Business Development | Profile | |
Anne Moore | Vice President Corporate Strategy | Profile | |
Gaetane Metz | Chief Operating Officer | Profile | |
Jaak Minten | Director Clinical Affairs, representing Fakkel SPRL | Profile | |
Roland GordonBeresford | Regulatory Affairs and IP Director | Profile | |
William Wijns | Non-Executive Director, permanent representative of the Cardiovascular Center Aalst CVBA | Profile | |
Hanspeter Spek | Non-Executive Director | Profile | |
JeanMarc Heynderickx | Independent Director | Profile | |
Serge Goblet | Non-Executive Director | Profile | |
Louise Proulx | Independent Director | Profile | |
Chris Buyse | Independent Director, permanent representative of Life Sciences Research Partners | Profile | |
Rudy Dekeyser | Independent Director | Profile | |
Margo Roberts | Director | Profile | |
Anne Portzenheim | Communication Manager | Profile | |
David Georges | VP Admin | Profile | |
MD MBChB | Chief Officer | Profile | |
Sara Zelkovic | Communications Director | Profile | |
Stephen Rubino | Chief Business Officer | Profile | |
Hannes Iserentant | Head Property | Profile | |
BME MBA | CFO, CoFounder | Profile | |
Dominic Piscitelli | Independent Director | Profile | |
Frdric Lehmann | VP Affairs | Profile | |
Maria Koehler | Independent Director | Profile | |
Philippe Nobels | Chief HR | Profile | |
An Phan | Head Legal | Profile | |
Philippe Dechamps | Chief Legal Officer | Profile | |
Marina UdierBlagovic | Director | Profile | |
Seron Aymeric | Program Manager | Profile |
About Celyad SA Management Performance
The success or failure of an entity such as Celyad SA often depends on how effective the management is. Celyad SA management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Celyad management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Celyad management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor-T cell-based therapies for the treatment of cancer. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium. CELYAD ONCOLOGY operates under Biotechnology classification in Belgium and is traded on Brussels Stock Exchange. It employs 87 people.
Celyad SA Workforce Analysis
Traditionally, organizations such as Celyad SA use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Celyad SA within its industry.Celyad SA Manpower Efficiency
Return on Celyad SA Manpower
Revenue Per Employee | 0.0 | |
Revenue Per Executive | 0.0 | |
Net Loss Per Employee | 279.1K | |
Net Loss Per Executive | 803.4K | |
Working Capital Per Employee | 1M | |
Working Capital Per Executive | 3M |
Additional Tools for Celyad Stock Analysis
When running Celyad SA's price analysis, check to measure Celyad SA's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Celyad SA is operating at the current time. Most of Celyad SA's value examination focuses on studying past and present price action to predict the probability of Celyad SA's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Celyad SA's price. Additionally, you may evaluate how the addition of Celyad SA to your portfolios can decrease your overall portfolio volatility.